£220bn
The total Gross Value
Added (GVA) of the
UK bioeconomy, according to the BBSRC
Contributions
invited
E x c l usi v it y is a k e y p a rt
i n se c uri n g f u n d i n g to
pro g ress y our te c h n o l o g y
to block similar products, as well
as direct copies.
• Extending the patent protection
sought – or keeping options open to
do so – across a geographical range
that fits with the need, and with
a profitable business model in the
future. Patents are territorial
and provide rights in a specific
geographical area (which can
often be just one country), so
it is important to consider the
geographical prevalence of a
particular disease, the willingness
of healthcare systems to pay for
the healthcare product being
developed, and where potential
generic competitors have nearby
manufacturing plants.
• Aligning a patenting strategy
and patent prosecution with R&D
results and the business plan. The
former can cause modifications to
the intended ultimate commercial
product, while the latter can
migrate under the influence of a
range of factors. Additionally, IP
teams should be able to spot when
the drug development programme
has produced a refinement or
incremental step which is itself
a patentable invention, as this
could create a new layer of
patent protection to strengthen
a patent portfolio.
• Ensuring that ownership and chain
of title are clear, since a business
cannot use a tool they do not own
or have suitable rights in.
• Being mindful of variations between
different jurisdictions for what can
be patentable, and building in means
to tailor the approach to claim
structure for different countries
or regions accordingly.
Editorial contributions are now invited
for the Winter issue, published in
November 2017. Our Winter issue will
focus on Smart Cities vs Urban Parks,
and clean energy. Contributions from
UKSPA members and tenants on
growth stories and best practice
case studies are also welcomed.
These factors can all have an impact
on your patent portfolio, and therefore
affect the strength and extent of
exclusivity for your innovation.
Exclusivity is a key part in securing
funding to progress your technology. ■
Copy deadline: Thursday 6 September
2017. Email your synopses to the
editor: [email protected]
To consider these in detail,
please contact Isobel via email
at [email protected]
or visit haseltinelake.com
Journal and
directory
advertising
In addition to advertising space in
Breakthrough, we also have space
available in the 2018 UKSPA Directory.
Please contact David Parker to
find out how these advertising
opportunities can best serve your
business objectives.
Tel: 01225 687267
[email protected]